Search research articles
Contact Us
Filters
Showing results (51-60 of 58) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 58 results.
The Lancet. Oncology
|
May 9, 2018
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
Susanne Saussele, Johan Richter, Joelle Guilhot, et al.
Journal of Clinical Medicine
|
July 26, 2020
A Cross-Sectional Retrospective Study of Non-Splenectomized and Never-Treated Patients with Type 1 Gaucher Disease
Christine Serratrice, Jérôme Stirnemann, Amina Berrahal, et al.
International Journal of Molecular Sciences
|
February 20, 2020
Immunoglobulin Abnormalities in Gaucher Disease: an Analysis of 278 Patients Included in the French Gaucher Disease Registry
Yann Nguyen, Jérôme Stirnemann, Florent Lautredoux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 12, 2024
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission
Francois-Xavier Mahon, Markus Pfirrmann, Stéphanie Dulucq, et al.
Journal of Internal Medicine
|
February 28, 2026
Increased intervals in enzyme replacement therapy for stable type 1 Gaucher disease: A non-inferiority sequential trial emulation
Maxime Beydon, Jérôme Stirnemann, Karima Yousfi, et al.
Journal of Inherited Metabolic Disease
|
May 10, 2025
Epidemiology of Gaucher Disease in France: Trends in Incidence, Mortality, Management, and Complications Over Three Decades
Yann Nguyen, Maxime Beydon, Karima Yousfi, et al.
Haematologica
|
May 26, 2022
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial
Stéphanie Dulucq, Franck E Nicolini, Delphine Rea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 12, 2019
Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients
Franck Emmanuel Nicolini, Stéphanie Dulucq, Lisa Boureau, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 58) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 58 results.
The Lancet. Oncology
|
May 9, 2018
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
Susanne Saussele, Johan Richter, Joelle Guilhot, et al.
Journal of Clinical Medicine
|
July 26, 2020
A Cross-Sectional Retrospective Study of Non-Splenectomized and Never-Treated Patients with Type 1 Gaucher Disease
Christine Serratrice, Jérôme Stirnemann, Amina Berrahal, et al.
International Journal of Molecular Sciences
|
February 20, 2020
Immunoglobulin Abnormalities in Gaucher Disease: an Analysis of 278 Patients Included in the French Gaucher Disease Registry
Yann Nguyen, Jérôme Stirnemann, Florent Lautredoux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 12, 2024
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission
Francois-Xavier Mahon, Markus Pfirrmann, Stéphanie Dulucq, et al.
Journal of Internal Medicine
|
February 28, 2026
Increased intervals in enzyme replacement therapy for stable type 1 Gaucher disease: A non-inferiority sequential trial emulation
Maxime Beydon, Jérôme Stirnemann, Karima Yousfi, et al.
Journal of Inherited Metabolic Disease
|
May 10, 2025
Epidemiology of Gaucher Disease in France: Trends in Incidence, Mortality, Management, and Complications Over Three Decades
Yann Nguyen, Maxime Beydon, Karima Yousfi, et al.
Haematologica
|
May 26, 2022
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial
Stéphanie Dulucq, Franck E Nicolini, Delphine Rea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 12, 2019
Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients
Franck Emmanuel Nicolini, Stéphanie Dulucq, Lisa Boureau, et al.
Page
of 6